- AbbVie's Stock Performance: Recent price drop amid a broader market downturn.
- Analyst Insights: Projected price target shows potential upside.
- GuruFocus Metrics: The GF Value suggests potential overvaluation.
AbbVie Inc. (ABBV, Financial) recently closed at $201.64, marking a 1.73% dip in a session when the S&P 500 suffered a significant 4.84% decline. Despite the broader market challenges, AbbVie has demonstrated resilience, outperforming the Medical sector over the past month. In comparison, AbbVie's stock saw a modest 3% decline, against the sector's steeper 4.6% loss. Investors are now turning their attention to the upcoming quarterly earnings report scheduled for April 25, 2025, anticipating an EPS of $2.51 and revenue reaching $12.92 billion.
Wall Street Analysts' Forecast
According to the projections from 24 analysts, AbbVie Inc (ABBV, Financial) has an average one-year price target of $215.43. This target range extends from a high estimate of $251.00 to a low of $173.00, indicating a potential upside of 6.84% from the current price of $201.64. For more in-depth estimate data, visit the AbbVie Inc (ABBV) Forecast page.
Market sentiment reflects optimism, with an average brokerage recommendation of 2.0 for AbbVie Inc (ABBV, Financial), translating to an "Outperform" status. This recommendation scale ranges from 1, denoting Strong Buy, to 5, which indicates Sell, as assessed by 27 different brokerage firms.
The GF Value calculated by GuruFocus for AbbVie Inc (ABBV, Financial) in one year stands at $167.94. This suggests a potential downside of 16.71% from the current trading price of $201.64. The GF Value is an estimation reflecting the stock's fair value, relying on historical trading multiples, past business growth trends, and future business performance estimates. For more comprehensive insights, please visit the AbbVie Inc (ABBV) Summary page.
